Research graph
References from Pharmacodynamic modeling of colistin and imipenem against in vitro Pseudomonas aeruginosa biofilms. Local targets link to admitted publications; unresolved targets remain external evidence.
Health care–associated infections: major issues in the early years of the 21st century
10.1086/518136 · 2007 · External reference
Microbial biofilms in pulmonary and critical care diseases
10.1513/annalsats.201603-194fr · 2016 · External reference
Effect of the endOclear device on biofilm in endotracheal tubes
10.1089/sur.2016.052 · 2017 · External reference
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus
10.1034/j.1399-3003.2000.16d30.x · 2000 · External reference
Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus
10.1016/j.jcf.2009.04.005 · 2009 · External reference
Applying insights from biofilm biology to drug development — can a new approach be developed?
10.1038/nrd4000 · 2013 · External reference
Structure-based prediction of anti-infective drug concentrations in the human lung epithelial lining fluid
10.1007/s11095-015-1832-x · 2016 · External reference
Validation of a model predicting anti-infective lung penetration in the epithelial lining fluid of humans
10.1007/s11095-017-2336-7 · 2018 · External reference
Antimicrobial resistance in bacteria: mechanisms, evolution, and persistence
10.1007/s00239-019-09914-3 · 2020 · External reference
Limitations of antibiotic MIC-based PK-PD metrics: looking back to move forward
10.3389/fphar.2021.770518 · 2021 · External reference
Distinct evolution of colistin resistance associated with experimental resistance evolution models in Klebsiella pneumoniae
10.1093/jac/dkaa450 · 2021 · External reference
Biomarker‐guided individualization of antibiotic therapy
10.1002/cpt.2194 · 2021 · External reference
Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs
10.1124/pr.111.005769 · 2013 · External reference
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations
2023 · External reference
Population pharmacokinetics of unbound and total teicoplanin in critically ill pediatric patients
2020 · External reference
Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies
10.1111/bcp.13016 · 2016 · External reference
Unresolved reference
2016 · External reference
Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms
10.1128/aac.00126-11 · 2011 · External reference
High β-lactamase levels change the pharmacodynamics of β-lactam antibiotics in Pseudomonas aeruginosa biofilms
10.1128/aac.01393-12 · 2013 · External reference
Colistin is extensively lost during standard in vitro experimental conditions
10.1128/aac.00857-17 · 2017 · External reference
Degradation kinetics of imipenem in normal saline and in human serum
10.1128/aac.29.5.936 · 1986 · External reference
Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa
10.1128/aac.40.4.904 · 1996 · External reference
Handling data below the limit of quantification in mixed effect models
10.1208/s12248-009-9112-5 · 2009 · External reference
The role of bystander effects in the antitumor activity of the hypoxia-activated prodrug PR-104
10.3389/fonc.2013.00263 · 2013 · External reference
Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients
10.1128/aac.03510-14 · 2014 · External reference
Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid
10.1111/bcp.12901 · 2016 · External reference
Virtual patient simulation using copula modeling
10.1002/cpt.3099 · 2024 · External reference
Generation of realistic virtual adult populations using a model-based copula approach
2024 · External reference
Interpretation of antibiotic concentration ratios measured in epithelial lining fluid
10.1128/aac.00133-06 · 2008 · External reference
Pharmacokinetics/Pharmacodynamics of pulmonary delivery of colistin against Pseudomonas aeruginosa in a mouse lung infection model
10.1128/aac.02025-16 · 2017 · External reference
Pharmacokinetic/Pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization
10.1128/aac.00182-11 · 2011 · External reference
Unresolved reference
2016 · External reference
Pseudomonas aeruginosa aggregate Formation in an alginate bead model System exhibits in vivo-like characteristics
10.1128/aem.00113-17 · 2017 · External reference
Diffusion retardation by binding of tobramycin in an alginate biofilm model
2016 · External reference
Antibiotic penetration and bacterial killing in a Pseudomonas aeruginosa biofilm model
10.1093/jac/dkv058 · 2015 · External reference
Pseudomonas aeruginosa biofilms
10.3390/ijms21228671 · 2020 · External reference
Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials
10.1128/jb.183.23.6746-6751.2001 · 2001 · External reference
Tolerance and resistance of microbial biofilms
10.1038/s41579-022-00682-4 · 2022 · External reference
In vitro evaluation of Pseudomonas aeruginosa chronic lung infection models: are agar and calcium-alginate beads interchangeable?
10.1016/j.ejpb.2019.08.006 · 2019 · External reference
Induction of beta-lactamase production in Pseudomonas aeruginosa biofilm
10.1128/aac.35.5.1008 · 1991 · External reference
Dynamics and spatial distribution of β-Lactamase expression in Pseudomonas aeruginosa biofilms
10.1128/aac.48.4.1168-1174.2004 · 2004 · External reference
Tolerance and persistence of Pseudomonas aeruginosa in biofilms exposed to antibiotics: molecular mechanisms, antibiotic strategies and therapeutic perspectives
10.3389/fmicb.2020.02057 · 2020 · External reference
Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa
10.1046/j.1365-2958.2003.03673.x · 2003 · External reference
Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB‐oprM genes
10.1111/j.1365-2958.2008.06152.x · 2008 · External reference
The metabolically active subpopulation in Pseudomonas aeruginosa biofilms survives exposure to membrane-targeting antimicrobials via distinct molecular mechanisms
10.1111/j.1574-695x.2012.00929.x · 2012 · External reference
Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections
10.1093/jac/dkz133 · 2019 · External reference
Pseudomonas aeruginosa biofilms exposed to Imipenem exhibit changes in global gene expression and β-Lactamase and alginate production
10.1128/aac.48.4.1175-1187.2004 · 2004 · External reference
Resistance to Imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms
10.1093/clinids/10.4.892 · 1988 · External reference
Effects of lung inflammation and injury on pulmonary tissue penetration of meropenem and vancomycin in a model of unilateral lung injury
10.1016/j.ijantimicag.2024.107180 · 2024 · External reference
Nebulized colistin and continuous cyclic Azithromycin in severe COPD patients with chronic bronchial infection due to Pseudomonas aeruginosa: a retrospective cohort Study
10.2147/copd.s209513 · 2019 · External reference
The efficacy and safety of intravenous colistin plus aerosolized colistin versus intravenous colistin alone in critically ill trauma patients with multi-drug resistant gram-negative Bacilli infection
2023 · External reference
In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection
10.1128/aac.06486-11 · 2012 · External reference
Impact of daptomycin dose exposure alone or in combination with β-lactams or rifampin against vancomycin-resistant enterococci in an in Vitro biofilm model
10.1128/aac.02074-19 · 2020 · External reference
In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm
10.1016/j.ijantimicag.2020.106246 · 2021 · External reference
Synergistic combinations of novel polymyxins and rifampicin with improved eradication of colistin-resistant Pseudomonas aeruginosa biofilms
10.1016/j.bioflm.2024.100224 · 2024 · External reference
Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data
10.1093/jac/dkx269 · 2017 · External reference
Model-Informed drug development in pulmonary delivery: semimechanistic pharmacokinetic–pharmacodynamic modeling for evaluation of treatments against chronic Pseudomonas aeruginosa lung infections
10.1021/acs.molpharmaceut.9b00968 · 2020 · External reference
Pharmacodynamic model of the dynamic response of Pseudomonas aeruginosa biofilms to antibacterial treatments
10.3390/biomedicines11082316 · 2023 · External reference
Effect of periodic disinfection on persisters in a one-dimensional biofilm model
10.1007/s11538-012-9796-z · 2013 · External reference
Biomarker‐guided individualization of antibiotic therapy
10.1002/cpt.2194 · ExternalCitation · doi-reference
Virtual patient simulation using copula modeling
10.1002/cpt.3099 · ExternalCitation · doi-reference
Antimicrobial resistance in bacteria: mechanisms, evolution, and persistence
10.1007/s00239-019-09914-3 · ExternalCitation · doi-reference
Structure-based prediction of anti-infective drug concentrations in the human lung epithelial lining fluid
10.1007/s11095-015-1832-x · ExternalCitation · doi-reference
Validation of a model predicting anti-infective lung penetration in the epithelial lining fluid of humans
10.1007/s11095-017-2336-7 · ExternalCitation · doi-reference
Effect of periodic disinfection on persisters in a one-dimensional biofilm model
10.1007/s11538-012-9796-z · ExternalCitation · doi-reference
Synergistic combinations of novel polymyxins and rifampicin with improved eradication of colistin-resistant Pseudomonas aeruginosa biofilms
10.1016/j.bioflm.2024.100224 · ExternalCitation · doi-reference
In vitro evaluation of Pseudomonas aeruginosa chronic lung infection models: are agar and calcium-alginate beads interchangeable?
10.1016/j.ejpb.2019.08.006 · ExternalCitation · doi-reference
In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm
10.1016/j.ijantimicag.2020.106246 · ExternalCitation · doi-reference
Effects of lung inflammation and injury on pulmonary tissue penetration of meropenem and vancomycin in a model of unilateral lung injury
10.1016/j.ijantimicag.2024.107180 · ExternalCitation · doi-reference
Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus
10.1016/j.jcf.2009.04.005 · ExternalCitation · doi-reference
Model-Informed drug development in pulmonary delivery: semimechanistic pharmacokinetic–pharmacodynamic modeling for evaluation of treatments against chronic Pseudomonas aeruginosa lung infections
10.1021/acs.molpharmaceut.9b00968 · ExternalCitation · doi-reference
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus
10.1034/j.1399-3003.2000.16d30.x · ExternalCitation · doi-reference
Applying insights from biofilm biology to drug development — can a new approach be developed?
10.1038/nrd4000 · ExternalCitation · doi-reference
Tolerance and resistance of microbial biofilms
10.1038/s41579-022-00682-4 · ExternalCitation · doi-reference
Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa
10.1046/j.1365-2958.2003.03673.x · ExternalCitation · doi-reference
Health care–associated infections: major issues in the early years of the 21st century
10.1086/518136 · ExternalCitation · doi-reference
Effect of the endOclear device on biofilm in endotracheal tubes
10.1089/sur.2016.052 · ExternalCitation · doi-reference
Resistance to Imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms
10.1093/clinids/10.4.892 · ExternalCitation · doi-reference
Distinct evolution of colistin resistance associated with experimental resistance evolution models in Klebsiella pneumoniae
10.1093/jac/dkaa450 · ExternalCitation · doi-reference
Antibiotic penetration and bacterial killing in a Pseudomonas aeruginosa biofilm model
10.1093/jac/dkv058 · ExternalCitation · doi-reference
Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data
10.1093/jac/dkx269 · ExternalCitation · doi-reference
Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections
10.1093/jac/dkz133 · ExternalCitation · doi-reference
Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid
10.1111/bcp.12901 · ExternalCitation · doi-reference
Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies
10.1111/bcp.13016 · ExternalCitation · doi-reference
Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB‐oprM genes
10.1111/j.1365-2958.2008.06152.x · ExternalCitation · doi-reference
The metabolically active subpopulation in Pseudomonas aeruginosa biofilms survives exposure to membrane-targeting antimicrobials via distinct molecular mechanisms
10.1111/j.1574-695x.2012.00929.x · ExternalCitation · doi-reference
Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs
10.1124/pr.111.005769 · ExternalCitation · doi-reference
Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms
10.1128/aac.00126-11 · ExternalCitation · doi-reference
Interpretation of antibiotic concentration ratios measured in epithelial lining fluid
10.1128/aac.00133-06 · ExternalCitation · doi-reference
Pharmacokinetic/Pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization
10.1128/aac.00182-11 · ExternalCitation · doi-reference
Colistin is extensively lost during standard in vitro experimental conditions
10.1128/aac.00857-17 · ExternalCitation · doi-reference
High β-lactamase levels change the pharmacodynamics of β-lactam antibiotics in Pseudomonas aeruginosa biofilms
10.1128/aac.01393-12 · ExternalCitation · doi-reference
Pharmacokinetics/Pharmacodynamics of pulmonary delivery of colistin against Pseudomonas aeruginosa in a mouse lung infection model
10.1128/aac.02025-16 · ExternalCitation · doi-reference
Impact of daptomycin dose exposure alone or in combination with β-lactams or rifampin against vancomycin-resistant enterococci in an in Vitro biofilm model
10.1128/aac.02074-19 · ExternalCitation · doi-reference
Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients
10.1128/aac.03510-14 · ExternalCitation · doi-reference
In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection
10.1128/aac.06486-11 · ExternalCitation · doi-reference
Degradation kinetics of imipenem in normal saline and in human serum
10.1128/aac.29.5.936 · ExternalCitation · doi-reference
Induction of beta-lactamase production in Pseudomonas aeruginosa biofilm
10.1128/aac.35.5.1008 · ExternalCitation · doi-reference
Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa
10.1128/aac.40.4.904 · ExternalCitation · doi-reference
Dynamics and spatial distribution of β-Lactamase expression in Pseudomonas aeruginosa biofilms
10.1128/aac.48.4.1168-1174.2004 · ExternalCitation · doi-reference
Pseudomonas aeruginosa biofilms exposed to Imipenem exhibit changes in global gene expression and β-Lactamase and alginate production
10.1128/aac.48.4.1175-1187.2004 · ExternalCitation · doi-reference
Pseudomonas aeruginosa aggregate Formation in an alginate bead model System exhibits in vivo-like characteristics
10.1128/aem.00113-17 · ExternalCitation · doi-reference
Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials
10.1128/jb.183.23.6746-6751.2001 · ExternalCitation · doi-reference
Handling data below the limit of quantification in mixed effect models
10.1208/s12248-009-9112-5 · ExternalCitation · doi-reference
Microbial biofilms in pulmonary and critical care diseases
10.1513/annalsats.201603-194fr · ExternalCitation · doi-reference
Nebulized colistin and continuous cyclic Azithromycin in severe COPD patients with chronic bronchial infection due to Pseudomonas aeruginosa: a retrospective cohort Study
10.2147/copd.s209513 · ExternalCitation · doi-reference
Tolerance and persistence of Pseudomonas aeruginosa in biofilms exposed to antibiotics: molecular mechanisms, antibiotic strategies and therapeutic perspectives
10.3389/fmicb.2020.02057 · ExternalCitation · doi-reference
The role of bystander effects in the antitumor activity of the hypoxia-activated prodrug PR-104
10.3389/fonc.2013.00263 · ExternalCitation · doi-reference
Limitations of antibiotic MIC-based PK-PD metrics: looking back to move forward
10.3389/fphar.2021.770518 · ExternalCitation · doi-reference
Pharmacodynamic model of the dynamic response of Pseudomonas aeruginosa biofilms to antibacterial treatments
10.3390/biomedicines11082316 · ExternalCitation · doi-reference
Pseudomonas aeruginosa biofilms
10.3390/ijms21228671 · ExternalCitation · doi-reference
